Hi everybody, my name is Brian John and I'm excited today to talk to you about hacking sub agents in the codeex CLI. So who am I. I'm a principal fullstack engineer.My current focus at work is AI enablement for R&D. So think helping our R&D team members get their work done faster and with higher quality using AI. The company I work for is BetterUp.It's an awesome place to work. We've been using AI since the very beginning. I've been there for over eight years now, which is longer than any place I've ever wo ...

Core Insights - Aeries Technology, Inc. has successfully completed a 100-day Go-Live ERP implementation for an enterprise client in North America, showcasing its capabilities in AI-driven business transformation [1][2] - The company emphasizes its consulting-led, AI-enabled execution model, which has helped clients achieve measurable operational gains by unifying critical business functions [2][3] - Aeries' digital transformation practice is focused on modernizing core enterprise functions, with a projected global digital transformation spending exceeding $3 trillion by 2030, positioning the company for sustained growth [3] Company Overview - Aeries Technology is recognized as a global leader in AI-enabled value creation and business transformation, particularly for private-equity portfolio companies [4] - The company has been awarded the Great Place to Work Certification for two consecutive years, reflecting its commitment to workforce development [4] Operational Achievements - A shift-left IT operations model implemented by Aeries optimized support ticket resolution by 80% and reduced IT resources by 41% [6] - The company automated the Accounts Payable process for a global services firm, reducing approval cycle times to under 48 hours and doubling process efficiency [6] - A rapid ERP deployment achieved full system migration, configuration, and user adoption in record time [6]

Financial Data and Key Metrics Changes - The company reported a revenue of $120 million for Q2 2025, reflecting a year-over-year growth of over 20% [5] - Adjusted EBITDA loss improved to $4.1 million in Q2 2025, a $4.6 million improvement compared to the same quarter last year [6][20] - Consolidated revenue increased by 21.5% to $119.8 million compared to Q2 2024 [15] - Gross profit for the quarter was $17.5 million, a 34% increase year-over-year, with a gross margin of 14.6% [16][17] Business Line Data and Key Metrics Changes - Patient services revenue was $55.9 million, a 7% increase year-over-year, representing 47% of total revenue [16] - Pharmacy revenue reached $62.6 million, up 41% year-over-year, now constituting 52% of total revenue [16] - The pharmacy business is forecasted to grow over 35% for the full year compared to the previous year [9] Market Data and Key Metrics Changes - The company added over 50,000 capitated lives in Nevada and California through new contracts effective in Q2 [6] - An expanded capitation relationship in Nevada added 49,000 Medicaid patients, and a verbal agreement in Florida will add over 40,000 Medicare Advantage lives [7][8] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA in Q4 2025, driven by strong growth in pharmacy and fee-for-service businesses [6][26] - The focus is on expanding capitated partnerships and leveraging technology to enhance operational efficiency [12][26] - The company is launching three AI enablement efforts in Q3 to improve performance and cost management [13][24] Management's Comments on Operating Environment and Future Outlook - Management noted that drug cost trends are increasing, but the company is positioned to provide value to payer partners through effective cost management [44][45] - The company expects to recognize revenue from new contracts in Q4 2025, with substantial growth anticipated in Florida [47][56] - Management expressed confidence in achieving the high end of the revenue guidance for 2025, projecting $460 million to $480 million [22] Other Important Information - The company announced the retirement of its current Chairman, Richard Barish, and the election of Anne McGeorge as the new Chair [13][14] - The company is focused on improving drug margins through strategic purchasing and active formulary management [21] Q&A Session Summary Question: Can you talk about the dispensing gross margin? - The increase in gross margin is attributed to improved drug procurement and scale, with significant growth year-over-year [28][30] Question: Thoughts on drug pricing reform impacts? - Management believes the Inflation Reduction Act will be net positive for the company, benefiting both capitated and fee-for-service margins [32][33] Question: Any specific drugs impacting EBITDA? - No significant risks were identified in the current drug portfolio that would impact EBITDA negatively [36] Question: Pressure on gross patient service margin? - The pressure is primarily from capitation margins, with expectations for improvement as new contracts mature [37][39] Question: Observations on oncology spend trends? - The company noted a stable medical loss ratio despite rising drug costs, indicating effective cost management [44][45] Question: Details on new patient contracts? - The company expects substantial growth in patient lives, particularly in Florida, with projections of around 100,000 Medicare Advantage lives by year-end [57][58] Question: Clarification on fully delegated risk arrangements? - The company clarified that it takes risk for Part B oncology services and has authority over utilization management and network design [61][62]